Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 61   

Articles published

ARNA 4.64 -0.02 (-0.43%)
price chart
A Valuation Model For Arena's Belviq
With Arena Pharmaceuticals' (ARNA) Belviq finally approved, Arena will be transitioning from being a cash-starved biotech into an earnings-generating one.
Related articles »  
Buy Arena Before European Approval Comes Through
Arena Pharmaceutical (NASDAQ:ARNA), a company operating in the healthcare sector, is involved in developing and commercializing drugs that target 'G-protein coupled receptors'.
Related articles »  
Insider Sales: Arena Pharmaceuticals, VIVUS Inc, Amarin Corporation
There has been an interesting trend among three noteworthy pharmaceutical companies like Arena Pharmaceuticals, Inc.
Vivus Looks Into European Approval As Company Pins Hopes On Qsymia  Seeking Alpha
Will pill-popping beat obesity?
Related articles »  
The Potential Market For Arena's Belviq
... because the product the company we invest in has real potential. There is a substantial difference between potential market and the real market for any given product.
What Slims Down Fastest After Diet Drugs Are Approved by he FDA? Two Stocks ...  YCharts
Related articles »  
Arena: Was This Pharmaceutical Stock a Pump and Dump?
These companies cannot be judged on their balance sheet because future earnings depend on FDA approval and successful sales and marketing.
Related articles »  
5 Bio-Pharma Stocks To Buy Right Here
Biotechnology and drug stocks offer some of the best potential for big gains in the market. The flip side of that proverbial coin, of course, is a great deal of risk.
Related articles »  
Short Interest in Biotech Firms on the Rise
Short interest data has been released from the August 15 settlement date. Overall short sellers have continued to bet on biotech firms compared to the July 31 settlement date.
Related articles »  
Simple Math Showing Why Synergy Pharmaceuticals Is Undervalued
In prior articles I've talked about Synergy Pharmaceuticals (NASDAQ:SGYP) as a fantastic under-the-radar biotech stock for 2012.
Related articles »  
Theravance: Buy This Biopharma On Weakness
The negative pricing action in just one short month is noticeably acute for biopharmaceutical companies obtaining FDA approvals but without a product to market.
Shattered Trust | Watchdog Update Hartland wipes manufacturer Triad files for ...
Triad Group Inc. and sister company H&P Industries Inc. are seeking protection from creditors under Chapter 11 - a provision that enables financially troubled firms to negotiate down their debts and continue in business.
Related articles »